Non-vitamin K Oral Anticoagulants and Anti-seizure Medications: A Retrospective Cohort Study
Purpose: Concerns of drug–drug interactions (DDIs) between anti-seizure medications (ASMs) and non-vitamin K oral anticoagulants (NOACs) have emerged in recent case reports and guidelines. Theoretically, the induction of hepatic cytochrome P450 3A4 (CYP3A4) enzyme and permeability glycoprotein (P-GP...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-02-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2020.588053/full |
id |
doaj-25bd43c00b9a43cb8966f038f1758122 |
---|---|
record_format |
Article |
spelling |
doaj-25bd43c00b9a43cb8966f038f17581222021-02-26T06:50:32ZengFrontiers Media S.A.Frontiers in Neurology1664-22952021-02-011110.3389/fneur.2020.588053588053Non-vitamin K Oral Anticoagulants and Anti-seizure Medications: A Retrospective Cohort StudyChen-Jui Ho0Shih-Hsuan Chen1Chih-Hsiang Lin2Yan-Ting Lu3Che-Wei Hsu4Meng-Han Tsai5Meng-Han Tsai6Department of Neurology, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, TaiwanDepartment of Neurology, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, TaiwanDepartment of Neurology, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, TaiwanDepartment of Neurology, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, TaiwanDepartment of Neurology, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, TaiwanDepartment of Neurology, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, TaiwanSchool of Medicine, College of Medicine, Chang Gung University, Taoyuan, TaiwanPurpose: Concerns of drug–drug interactions (DDIs) between anti-seizure medications (ASMs) and non-vitamin K oral anticoagulants (NOACs) have emerged in recent case reports and guidelines. Theoretically, the induction of hepatic cytochrome P450 3A4 (CYP3A4) enzyme and permeability glycoprotein (P-GP) efflux transporter protein systems may reduce the effect of NOACs. We aimed to investigate whether such DDIs are clinically relevant in a real-world situation.Methods: We retrospectively reviewed 320 ischemic stroke patients with atrial fibrillation (Af) and grouped them according to different potential interactions with CYP3A4 and P-GP. Ischemic stroke events, transient ischemic attack (TIA) events, follow-up duration, baseline characteristics, concomitant ASMs, and stroke risk factors were collected. Statistical analysis included Kaplan–Meier survival curves and the log-rank test.Results: Overall, 320 ischemic stroke with Af patients received NOACs. Among the NOAC users, 75 also took ASMs, including 56 that have potential DDIs: 43 (13.4%) were categorized as potential CYP and P-GP DDIs and 13 (4.1%) as P-GP-only DDIs. The remaining 264 (82.5%) patients were used as controls including 19 exposed to nonsignificant DDI ASMs and 245 patients without ASM exposure. The incidence rates of recurrent stroke/TIA events in both CYP3A4 and P-GP DDIs, P-GP DDIs only, and no DDIs were 7.5, 2.1, and 8.4/100 person-years, respectively. Kaplan–Meier survival curves and the log-rank test did not show significant differences among the groups.Conclusions: The recurrent stroke rate of NOAC users with potential DDIs was not higher than in those without potential DDIs in this single-institute study. Our results suggest that theoretical interactions between ASMs and NOACs may not be as severe as previously thought in a real-world situation.https://www.frontiersin.org/articles/10.3389/fneur.2020.588053/fullepilepsyASMdrug–drug interactionstrokeNOAC |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Chen-Jui Ho Shih-Hsuan Chen Chih-Hsiang Lin Yan-Ting Lu Che-Wei Hsu Meng-Han Tsai Meng-Han Tsai |
spellingShingle |
Chen-Jui Ho Shih-Hsuan Chen Chih-Hsiang Lin Yan-Ting Lu Che-Wei Hsu Meng-Han Tsai Meng-Han Tsai Non-vitamin K Oral Anticoagulants and Anti-seizure Medications: A Retrospective Cohort Study Frontiers in Neurology epilepsy ASM drug–drug interaction stroke NOAC |
author_facet |
Chen-Jui Ho Shih-Hsuan Chen Chih-Hsiang Lin Yan-Ting Lu Che-Wei Hsu Meng-Han Tsai Meng-Han Tsai |
author_sort |
Chen-Jui Ho |
title |
Non-vitamin K Oral Anticoagulants and Anti-seizure Medications: A Retrospective Cohort Study |
title_short |
Non-vitamin K Oral Anticoagulants and Anti-seizure Medications: A Retrospective Cohort Study |
title_full |
Non-vitamin K Oral Anticoagulants and Anti-seizure Medications: A Retrospective Cohort Study |
title_fullStr |
Non-vitamin K Oral Anticoagulants and Anti-seizure Medications: A Retrospective Cohort Study |
title_full_unstemmed |
Non-vitamin K Oral Anticoagulants and Anti-seizure Medications: A Retrospective Cohort Study |
title_sort |
non-vitamin k oral anticoagulants and anti-seizure medications: a retrospective cohort study |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Neurology |
issn |
1664-2295 |
publishDate |
2021-02-01 |
description |
Purpose: Concerns of drug–drug interactions (DDIs) between anti-seizure medications (ASMs) and non-vitamin K oral anticoagulants (NOACs) have emerged in recent case reports and guidelines. Theoretically, the induction of hepatic cytochrome P450 3A4 (CYP3A4) enzyme and permeability glycoprotein (P-GP) efflux transporter protein systems may reduce the effect of NOACs. We aimed to investigate whether such DDIs are clinically relevant in a real-world situation.Methods: We retrospectively reviewed 320 ischemic stroke patients with atrial fibrillation (Af) and grouped them according to different potential interactions with CYP3A4 and P-GP. Ischemic stroke events, transient ischemic attack (TIA) events, follow-up duration, baseline characteristics, concomitant ASMs, and stroke risk factors were collected. Statistical analysis included Kaplan–Meier survival curves and the log-rank test.Results: Overall, 320 ischemic stroke with Af patients received NOACs. Among the NOAC users, 75 also took ASMs, including 56 that have potential DDIs: 43 (13.4%) were categorized as potential CYP and P-GP DDIs and 13 (4.1%) as P-GP-only DDIs. The remaining 264 (82.5%) patients were used as controls including 19 exposed to nonsignificant DDI ASMs and 245 patients without ASM exposure. The incidence rates of recurrent stroke/TIA events in both CYP3A4 and P-GP DDIs, P-GP DDIs only, and no DDIs were 7.5, 2.1, and 8.4/100 person-years, respectively. Kaplan–Meier survival curves and the log-rank test did not show significant differences among the groups.Conclusions: The recurrent stroke rate of NOAC users with potential DDIs was not higher than in those without potential DDIs in this single-institute study. Our results suggest that theoretical interactions between ASMs and NOACs may not be as severe as previously thought in a real-world situation. |
topic |
epilepsy ASM drug–drug interaction stroke NOAC |
url |
https://www.frontiersin.org/articles/10.3389/fneur.2020.588053/full |
work_keys_str_mv |
AT chenjuiho nonvitaminkoralanticoagulantsandantiseizuremedicationsaretrospectivecohortstudy AT shihhsuanchen nonvitaminkoralanticoagulantsandantiseizuremedicationsaretrospectivecohortstudy AT chihhsianglin nonvitaminkoralanticoagulantsandantiseizuremedicationsaretrospectivecohortstudy AT yantinglu nonvitaminkoralanticoagulantsandantiseizuremedicationsaretrospectivecohortstudy AT cheweihsu nonvitaminkoralanticoagulantsandantiseizuremedicationsaretrospectivecohortstudy AT menghantsai nonvitaminkoralanticoagulantsandantiseizuremedicationsaretrospectivecohortstudy AT menghantsai nonvitaminkoralanticoagulantsandantiseizuremedicationsaretrospectivecohortstudy |
_version_ |
1724249782458777600 |